Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 22Vitamin D Deficiency 20Prostatic Neoplasms 17Polycystic Ovary Syndrome 10Neoplasms 9Colonic Neoplasms 8Rectal Neoplasms 6Colorectal Neoplasms 6Osteoporosis 5Myelodysplastic Syndromes 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Cardiovascular Diseases 4Warts 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Brain Neoplasms 3Adenomatous Polyps 3Pathologic Processes 2Pain 2Obesity 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Musculoskeletal Diseases 2Melanoma 2Male Urogenital Diseases 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vitamin D3 × Cholecalciferol × Clear all
NCT03389659 2018-01-03

XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
750 enrolled

Vitamin D3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡